Yes, there are a new class of biologics that are oral, called JAK inhibitors.  This includes a medication called tofacitinib (Xeljanz) that has been studied in children with polyarticular JIA. These medications will become more commonly used in a variety of diseases, and hopefully more available to children and teens.